Chardan Capital Reiterates Buy Rating for PRQR
Chardan Capital maintains its buy rating on PRQR with a $3 price target, a 91.69% upside from the current price.
Key Points
- Chardan Capital reiterated its buy rating for PRQR, setting a $3 price target on June 26, 2026.
- Chardan Capital's $3 price target implies 91.69% upside from ProQR Therapeutics N.V.'s ($PRQR) current $1.56 share price.
- PRQR shares traded at $1.56 on Friday, with notable institutional activity from peers such as Privium Fund Management and Aberdeen Group.
- Insider Hinsch Gylvin Lykke bought 14,495 shares on June 2, 2026, reflecting ongoing interest in the company.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital has reiterated its buy rating for PRQR, setting a price target of $3. This announcement was made on June 26, 2026, by analyst Keay Nakae. On the same day, PRQR shares were trading at $1.56.
Other Institutional Activity in PRQR
Several institutional investors have been active in PRQR. Privium Fund Management B.V. increased its holdings by 109,387 shares, bringing its total to 5,467,149 shares valued at approximately $8.86 million, marking a 2.0% increase. Aberdeen Group PLC also grew its stake by 366,289 shares, totaling 3,316,965 shares worth about $5.37 million, reflecting a 12.4% increase. Conversely, SIO Capital Management, LLC reduced its holdings by 209,466 shares, ending with 1,954,715 shares valued at roughly $3.17 million, a decrease of 9.7%.
ProQR Therapeutics N.V. Stock Down 31.7%
Shares of PRQR traded at $1.56 on Friday. The stock has seen varied activity among institutional investors, with some increasing their positions and others trimming their stakes. This mixed activity highlights the diverse perspectives on the company's potential.
$PRQR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at ProQR Therapeutics N.V.
On June 2, 2026, insider Hinsch Gylvin Lykke purchased 14,495 shares of PRQR. This transaction was not pre-planned under a Rule 10b5-1 plan, indicating a direct investment decision.
Analysts Set New Price Targets
On June 26, 2026, Chardan Capital maintained its buy rating for PRQR with a price target of $3. This follows a previous target of $4 set on April 9, 2026. The consensus among analysts remains positive, with a general buy recommendation.
Bottom Line
Chardan Capital's reiterated buy rating for PRQR with a $3 target reflects continued confidence in the company's prospects. Institutional and insider activities suggest varying levels of interest and investment strategies. As always, these analyst ratings and institutional moves are backward-looking and should be considered as part of a broader investment strategy.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.